Glucagon-like peptide-2 analog in treatment of short bowel syndrome
Keywords:
teduglutide, short bowel, glucagon-like petide, parenteral supportAbstract
Teduglutide, a glucagon-like peptide 2 analog, is approved to enhance the intestinal absorptive ability in short bowel syndrome patients aged ≥ 1 year,following a period of postsurgical intestinal adaptation.A 6-month, phase III study of subcutaneous teduglutide 0.05 mg/kg/d compared to placebo in adults with short bowel dependent on parenteral support (PS) showed that the number of patientswho achieved a reduction in PS volume of 20% or more after drug initiationwas significantly higher in the teduglutide group. A significantly greater proportion of patients who had a reduction in one or more days on PS was also found in patients treated with teduglutide compared with the placebo group. Increased intestinal absorptive ability and decreased PS requirement can be maintained for a period of time after discontinuing the drug. Similar results were also found in pediatric patients. Adverse effects were reported as abdominal pain,abdominal distension,flatulence,diarrhea, nausea, vomiting, etc.Teduglutide is relatively expensive and not yet considered cost-effective, according toa cost-effectiveness analysis based on current clinical studies.There have been some reports of teduglutide risk factors, such as of duodenal polyps or gastrointestinal cancers. Long-term safety surveillance is still required.
References
Pironi L, Arends J, Baxter J, Bozzetti F, Peláez RB, Cuerda C, et al. ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults. Clin Nutr. 2015;34(2):171-80.
Warner BW. The pathogenesis of resection-associated intestinal adaptation. Cell Mol Gastroenterol Hepatol. 2016;2(4):429-38.
Jeppesen PB. Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome. Therap Adv Gastroenterol. 2012;5(3):159-71.
Rintala RJ, Pakarinen M, Wester T. Current Concepts of Intestinal Failure. AG, Switzerland: Springer International Publishing; 2016. ISBN 978-3-319-42551-1
Duggan CP, Jaksic T. Pediatric intestinal failure. NEJM. 2017;377(7):666-75.
Dimitriadis GK, Miras AD. Glucagon-like peptide-2 (GLP-2). In: Huhtaniemi I, Martini L, editors. Encyclopedia of Endocrine Diseases (Second Edition). Oxford: Academic Press; 2018. p. 561-4.
Brubaker PL, Anini Y. Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Can J Physiol Pharmacol. 2003;81(11):1005-12.
Warner BW. Adaptation: paradigm for the gut and an academic career. J Pediatr Surg. 2013;48(1):20-6.
Baldassano S, Amato A, Cappello F, Rappa F, Mulè F. Glucagon-like peptide-2 and mouse intestinal adaptation to a high-fat diet. J Endocrinol. 2013;217(1):11-20.
Hartmann B, Harr MB, Jeppesen PB, Wojdemann M, Deacon CF, Mortensen PB, et al. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab. 2000;85(8):2884-8.
Marier JF, Beliveau M, Mouksassi MS, Shaw P, Cyran J, Kesavan J, et al. Pharmacokinetics, safety, and tolerability of Teduglutide, a Glucagon-Like Peptide-2 (GLP-2) Analog, Following Multiple Ascending Subcutaneous Administrations in Healthy Subjects. J Clin Pharmacol. 2008;48(11):1289-99.
Burness CB, McCormack PL. Teduglutide: A review of its use in the treatment of patients with short bowel syndrome. Drugs. 2013;73(9):935-47.
McKeage K. Teduglutide: A guide to its use in short bowel syndrome. Clin Drug Investig. 2015;35(5):335-40.
Kim ES, Keam SJ. Teduglutide: A review in short bowel syndrome. Drugs. 2017;77(3):345-52.
European Medicine Agency. Revestive: EPAR product information; summary of product characteristics. 2018 [cited 2019/01/09]. Available from: https://www.ema.europa.eu/documents/product-information/revestive-epar-product-information_en.pdf
Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B, O'Keefe SJD. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut. 2011;60(7):902-14.
Jeppesen PB, Pertkiewicz M, Messing B, Iyer K, Seidner DL, O'Keefe SJD, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012;143(6):1473-81.
Schwartz LK, O’Keefe SJD, Fujioka K, Gabe SM, Lamprecht G, Pape U-F, et al. Long-term teduglutide for the treatment of patients with intestinal failure associated with short bowel syndrome. Clin Transl Gastroenterol. 2016;7:e142.
Seidner DL, Fujioka K, Boullata JI, Iyer K, Lee H-M, Ziegler TR. Reduction of parenteral nutrition and hydration support and safety with long-term teduglutide treatment in patients with short bowel syndrome-associated intestinal failure: STEPS-3 study. Nutr Clin Prac. 2018;33(4):520-7.
Iyer KR, Kunecki M, Boullata JI, Fujioka K, Joly F, Gabe S, et al. Independence from parenteral nutrition and intravenous fluid support during treatment with teduglutide among patients with intestinal failure associated with short bowel syndrome. JPEN J Parenter Enteral Nutr. 2017;41(6):946-51.
Jeppesen PB, Gabe SM, Seidner DL, Lee H-M, Olivier C. Factors associated with response to teduglutide in patients with short-bowel syndrome and intestinal failure. Gastroenterology. 2018;154(4):874-85.
Ukleja A, Alkhairi B, Bejarano P, Podugu A. De novo development of hamartomatous duodenal polyps in a patient with short bowel syndrome during teduglutide therapy: A case report. JPEN J Parenter Enteral Nutr. 2018;42(3):658-60.
Rudzki S, Armstrong D, Jeppesen PB, Forbes A, Lee HM. MON-P083: Post HOC analysis of polyps in 9 short bowel syndrome patients treated with teduglutide. Clin Nutr. 2016;35:S183-S4.
Carter BA, Cohran VC, Cole CR, Corkins MR, Dimmitt RA, Duggan C, et al. Outcomes from a 12-Week, open-label, multicenter clinical trial of teduglutide in pediatric short bowel syndrome. J Pediatr. 2017;181:102-11.e5.
Vipperla K, O'Keefe SJ. Targeted therapy of short-bowel syndrome with teduglutide: the new kid on the block. Clin Exp Gastroenterol. 2014;7:489-95.
Shire. Study in Japanese pediatric subjects with short bowel syndrome (SBS) who are dependent on parenteral support. [cited 19 April 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT02980666.
Shire. A study in Japanese children with short bowel syndrome who completed SHP633-302. [cited 19 April 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT03268811.
National Centre for Pharmacoeconomics. Cost-effectiveness of teduglutide (Revestive®) for the treatment of patients aged one year and above with short bowel syndrome. 2018 [cited 2019/01/10]. Available from: http://www.ncpe.ie/wp-content/uploads/2017/04/Summary-for-website-16.03.2018.pdf.
Downloads
Published
How to Cite
Issue
Section
License
The content and information in the articles published in Thai JPEN วารสารโภชนบำบัด, are the opinions and responsibility of the authors directly. The editorial team is not obliged to agree or take any responsibility.
All articles, content, figures, etc. that have been published in Thai JPEN วารสารโภชนบำบัด are the copyright of Thai JPEN วารสารโภชนบำบัด. If any person or organization require distribution of all or any part of them, please send the request for the written permission from Thai JPEN วารสารโภชนบำบัด only.
